MALACHITE INNOVATIONS REPORTS THIRD QUARTER 2023 RESULTS
- Record financial results with significant increases in revenue, gross profit, operating income, net income, and adjusted EBITDA.
- Successful completion of a large $2.4 million reclamation contract and acquisition of a reclamation company.
- Launch of a land acquisition strategy for a renewable energy project with the purchase of 1,900 acres of former mine land.
- None.
CLEVELAND, OHIO, Nov. 14, 2023 (GLOBE NEWSWIRE) -- MALACHITE INNOVATIONS, INC. (OTC Mkts: MLCT) (“Malachite”), a public company focused on improving the health and wellness of people and the planet, reported its results for the quarter ended September 30, 2023.
Malachite’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 was filed with the Securities and Exchange Commission on November 14, 2023 and is available for viewing at https://malachiteinnovations.com/investors/. Since the information provided in this press release is limited to selected financial and operational information, investors and interested parties are encouraged to read Malachite’s full Form 10-Q available on its website.
With respect to the latest quarterly results, Michael Cavanaugh, Malachite’s CEO, commented, “I am proud to report that the Company has posted record financial results for the fifth consecutive quarter with sales of
Third Quarter 2023 Financial Highlights
- Revenue |
$5,455,633 in 3Q 2023 versus$1,547,258 in 3Q 2022, an increase of$3,908,375 , and$15,114,448 in the last 12-month (“LTM”) period ending September 30, 2023 versus$2,186,617 in the LTM period ending September 30, 2022, an increase of$12,927,831. - Gross Profit |
$2,857,766 in 3Q 2023 versus$357,783 in 3Q 2022, an increase of$2,499,983 , and$5,322,386 in the LTM period ending September 30, 2023 versus$422,735 in the LTM period ending September 30, 2022, an increase of$4,899,651. - Operating Income (Loss) |
$1,659,871 in 3Q 2023 versus ($198,002) in 3Q 2022, an improvement of$1,857,873 , and$1,542,844 in the LTM period ending September 30, 2023 versus ($1,660,959) in the LTM period ending September 30, 2022, an improvement of$3,203,803. - Net Income (Loss) |
$3,404,175 in 3Q 2023 versus ($119,616) in 3Q 2022, an improvement of$3,523,791 , and$3,152,677 in the LTM period ending September 30, 2023 versus ($1,607,152) in the LTM period ending September 30, 2022, an improvement of$4,759,829. $1,875,150 of the improvement is due to a non-cash bargain purchase gain resulting from the Collins Building acquisition that has been recorded in 3Q 2023. - Adjusted EBITDA |
$2,056,257 in 3Q 2023 versus$48,195 in 3Q 2022, an improvement of$2,008,062 , and$3,267,704 in the LTM period ending September 30, 2023 versus ($1,108,212) in the LTM period ending September 30, 2022, an improvement of$4,375,916. - Cash Flow from Operations |
$1,473,118 in 3Q 2023 versus$276,532 in 3Q 2022, an improvement of$1,196,586 , and$1,750,766 in the LTM period ending September 30, 2023 versus ($988,568) in the LTM period ending September 30, 2022, an improvement of$2,739,334.
Third Quarter 2023 Consolidated Financial Highlights
| 3Q 2023 | 3Q 2022 | 3Q 2023 LTM | 3Q 2022 LTM | |||||||||||||
| Revenue | $ | 5,455,633 | $ | 1,547,258 | $ | 15,114,448 | $ | 2,186,617 | ||||||||
| Cost of Goods Sold | 2,597,867 | 1,189,475 | 9,792,062 | 1,763,882 | ||||||||||||
| Gross Profit | 2,857,766 | 357,783 | 5,322,386 | 422,735 | ||||||||||||
| Operating Expenses | 1,197,895 | 555,785 | 3,779,542 | 2,083,694 | ||||||||||||
| Operating Income (Loss) | 1,659,871 | (198,002 | ) | 1,542,844 | (1,660,959 | ) | ||||||||||
| Other Income | 1,744,304 | 78,386 | 1,609,833 | 53,807 | ||||||||||||
| Net Income (Loss) | 3,404,175 | (119,616 | ) | 3,152,677 | (1,607,152 | ) | ||||||||||
| Non-Cash Expenses | (1,483,385 | ) | 132,531 | (150,675 | ) | 439,368 | ||||||||||
| Working Capital Changes | (447,672 | ) | 263,617 | (1,251,236 | ) | 179,216 | ||||||||||
| Cash Flow from Operations | $ | 1,473,118 | $ | 276,532 | $ | 1,750,766 | $ | (988,568 | ) | |||||||
| Gross Profit Margin % | 52.4 | % | 23.1 | % | 35.2 | % | 19.3 | % | ||||||||
| Operating Profit Margin % | 30.4 | % | -12.8 | % | 10.2 | % | -76.0 | % | ||||||||
| Net Income Margin % | 62.4 | % | -7.7 | % | 20.9 | % | -73.5 | % | ||||||||
| Cash Flow from Operations Margin % | 27.0 | % | 17.9 | % | 11.6 | % | -45.2 | % | ||||||||
Third Quarter 2023 Segmented Financial Highlights
| 3Q 2023 | 3Q 2022 | 3Q 2023 LTM | 3Q 2022 LTM | |||||||||||||
| Revenue | ||||||||||||||||
| Range Reclaim | $ | 5,299,415 | $ | 1,547,258 | $ | 14,816,055 | $ | 2,186,617 | ||||||||
| Range Water | - | - | - | - | ||||||||||||
| Range Security | 156,218 | - | 298,393 | - | ||||||||||||
| Range Land | - | - | - | - | ||||||||||||
| Drug Development | - | - | - | - | ||||||||||||
| Corporate | - | - | - | - | ||||||||||||
| Total Revenue | $ | 5,455,633 | $ | 1,547,258 | $ | 15,114,448 | $ | 2,186,617 | ||||||||
| Gross Profit | ||||||||||||||||
| Range Reclaim | $ | 2,784,912 | $ | 357,783 | $ | 5,183,695 | $ | 422,735 | ||||||||
| Range Water | - | - | - | - | ||||||||||||
| Range Security | 72,854 | - | 138,691 | - | ||||||||||||
| Range Land | - | - | - | - | ||||||||||||
| Drug Development | - | - | - | - | ||||||||||||
| Corporate | - | - | - | - | ||||||||||||
| Total Gross Profit | $ | 2,857,766 | $ | 357,783 | $ | 5,322,386 | $ | 422,735 | ||||||||
| Net Income (Loss) | ||||||||||||||||
| Range Reclaim | $ | 4,048,527 | $ | 213,865 | $ | 5,331,842 | $ | 136,235 | ||||||||
| Range Water | (15,376 | ) | - | (53,656 | ) | - | ||||||||||
| Range Security | 50,555 | - | 71,000 | - | ||||||||||||
| Range Land | - | - | - | - | ||||||||||||
| Drug Development | (140,840 | ) | (106,744 | ) | (484,967 | ) | (473,572 | ) | ||||||||
| Corporate | (538,691 | ) | (226,737 | ) | (1,711,542 | ) | (1,269,815 | ) | ||||||||
| Total Net Income (Loss) | $ | 3,404,175 | $ | (119,616 | ) | $ | 3,152,677 | $ | (1,607,152 | ) | ||||||
| Adjusted EBITDA | ||||||||||||||||
| Range Reclaim | $ | 2,637,714 | $ | 368,246 | $ | 4,947,149 | $ | 357,031 | ||||||||
| Range Water | (14,736 | ) | - | (52,590 | ) | - | ||||||||||
| Range Security | 53,446 | - | 78,434 | - | ||||||||||||
| Range Land | - | - | - | - | ||||||||||||
| Drug Development | (140,840 | ) | (106,744 | ) | (484,967 | ) | (473,572 | ) | ||||||||
| Corporate | (479,327 | ) | (213,307 | ) | (1,220,322 | ) | (991,671 | ) | ||||||||
| Total Adjusted EBITDA | $ | 2,056,257 | $ | 48,195 | $ | 3,267,704 | $ | (1,108,212 | ) | |||||||
Third Quarter 2023 Reconciliation of Net Income (Loss) to Adjusted EBITDA
| 3Q 2023 | 3Q 2022 | 3Q 2023 LTM | 3Q 2022 LTM | |||||||||||||
| Net Income (Loss) | ||||||||||||||||
| Range Reclaim | $ | 4,048,527 | $ | 213,865 | $ | 5,331,842 | $ | 136,235 | ||||||||
| Range Water | (15,376 | ) | - | (53,656 | ) | - | ||||||||||
| Range Security | 50,555 | - | 71,000 | - | ||||||||||||
| Range Land | - | - | - | - | ||||||||||||
| Drug Development | (140,840 | ) | (106,744 | ) | (484,967 | ) | (473,572 | ) | ||||||||
| Corporate | (538,691 | ) | (226,737 | ) | (1,711,542 | ) | (1,269,815 | ) | ||||||||
| Total Net Income (Loss) | $ | 3,404,175 | $ | (119,616 | ) | $ | 3,152,677 | $ | (1,607,152 | ) | ||||||
| Interest | ||||||||||||||||
| Range Reclaim | $ | 93,933 | $ | 17,618 | $ | 225,500 | $ | 28,641 | ||||||||
| Range Water | - | - | - | - | ||||||||||||
| Range Security | - | - | 224 | - | ||||||||||||
| Range Land | - | - | - | - | ||||||||||||
| Drug Development | - | - | - | - | ||||||||||||
| Corporate | 41,534 | 13,430 | 44,210 | 26,699 | ||||||||||||
| Total Interest | $ | 135,467 | $ | 31,048 | $ | 269,934 | $ | 55,340 | ||||||||
| Taxes | ||||||||||||||||
| Range Reclaim | $ | - | $ | - | $ | - | $ | - | ||||||||
| Range Water | - | - | - | - | ||||||||||||
| Range Security | - | - | - | - | ||||||||||||
| Range Land | - | - | - | - | ||||||||||||
| Drug Development | - | - | - | - | ||||||||||||
| Corporate | - | - | - | - | ||||||||||||
| Total Taxes | $ | - | $ | - | $ | - | $ | - | ||||||||
| Depreciation | ||||||||||||||||
| Range Reclaim | $ | 370,404 | $ | 136,763 | $ | 1,264,957 | $ | 192,155 | ||||||||
| Range Water | 640 | - | 1,066 | - | ||||||||||||
| Range Security | 2,891 | - | 7,210 | - | ||||||||||||
| Range Land | - | - | - | - | ||||||||||||
| Drug Development | - | - | - | - | ||||||||||||
| Corporate | - | - | - | - | ||||||||||||
| Total Depreciation | $ | 373,935 | $ | 136,763 | $ | 1,273,233 | $ | 192,155 | ||||||||
| Non-Cash Adjustments | ||||||||||||||||
| Range Reclaim | $ | (1,875,150 | ) | $ | - | $ | (1,875,150 | ) | $ | - | ||||||
| Range Water | - | - | - | - | ||||||||||||
| Range Security | - | - | - | - | ||||||||||||
| Range Land | - | - | - | - | ||||||||||||
| Drug Development | - | - | - | - | ||||||||||||
| Corporate | 17,830 | - | 447,010 | 251,445 | ||||||||||||
| Total Non-Cash Adjustments | $ | (1,857,320 | ) | $ | - | $ | (1,428,140 | ) | $ | 251,445 | ||||||
| Adjusted EBITDA | ||||||||||||||||
| Range Reclaim | $ | 2,637,714 | $ | 368,246 | $ | 4,947,149 | $ | 357,031 | ||||||||
| Range Water | (14,736 | ) | - | (52,590 | ) | - | ||||||||||
| Range Security | 53,446 | - | 78,434 | - | ||||||||||||
| Range Land | - | - | - | - | ||||||||||||
| Drug Development | (140,840 | ) | (106,744 | ) | (484,967 | ) | (473,572 | ) | ||||||||
| Corporate | (479,327 | ) | (213,307 | ) | (1,220,322 | ) | (991,671 | ) | ||||||||
| Total Adjusted EBITDA | $ | 2,056,257 | $ | 48,195 | $ | 3,267,704 | $ | (1,108,212 | ) | |||||||
Non-GAAP Financial Information
In addition to our results under Generally Accepted Accounting Principles (“GAAP”), in this release we also present certain other supplemental measures of financial performance that are not required by or presented in accordance with GAAP, including Adjusted Earnings Before Interest Taxes Depreciation and Amortization (“Adjusted EBITDA”). We calculate Adjusted EBITDA as net income (loss) before interest expense, income tax expense, depreciation and amortization, and non-cash stock-based compensation expenses related to restricted stock grants and stock options issued to directors and employees and consultants. Adjusted EBITDA is one of the primary metrics used by management to evaluate our financial performance, analyze the effectiveness of our business strategies, and make budgeting and capital allocation decisions. However, this non-GAAP measure does have certain limitations and should not be considered as an alternative to net income (loss), earnings (loss) per share or any other performance measures derived in accordance with GAAP.
About Malachite Innovations, Inc.
Headquartered in Cleveland, Ohio, Malachite Innovations, Inc. is a public company dedicated to improving the health and wellness of people and the planet through a novel and innovative approach to impact investing. Malachite owns and operates several complementary operating businesses focused on developing long-term solutions to environmental, social, and health challenges, with a particular focus on economically disadvantaged communities. Malachite takes an opportunistic approach to impact investing by leveraging its competitive advantages and looking at solving old problems in new ways. Malachite seeks to thoughtfully allocate its capital into strategic opportunities that are expected to make a positive impact on the people-planet ecosystem and generate strong investment returns for its shareholders.
Notice Regarding Forward-Looking Statements
This press release contains “forward-looking statements” as that term is defined in Section 27(a) of the Securities Act of 1933, as amended and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Although we believe that these statements are based on reasonable assumptions, they are subject to numerous factors that could cause actual outcomes and results to be materially different from those indicated in such statements. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies, timing of clinical trials and product development, business strategy and new lines of business. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
Malachite Innovations, Inc.
Investor Relations
P: +1 (216) 304-6556
E: ir@malachiteinnovations.com
W: www.malachiteinnovations.com
FAQ
What are Malachite Innovations, Inc.'s financial results for the quarter ended September 30, 2023?
What growth strategies did Malachite Innovations, Inc. execute in 3Q 2023?
What were the key financial highlights for Malachite Innovations, Inc. in 3Q 2023?
